Measure: CMS130
Colorectal Cancer Screening
Measure Versions
| eMeasure Code |
Measure Year |
Full Version Number |
Title |
| CMS130v12 |
2024 |
12.0.000 |
Colorectal Cancer Screening |
| CMS130v11 |
2023 |
11 |
Colorectal Cancer Screening |
| CMS130v10 |
2022 |
10.0.000 |
Colorectal Cancer Screening |
| CMS130v9 |
2021 |
9.2.000 |
Colorectal Cancer Screening |
| CMS130v8 |
2020 |
8.4.000 |
Colorectal Cancer Screening |
| CMS130v7 |
2019 |
7.2.000 |
Colorectal Cancer Screening |
| CMS130v6 |
2018 |
6.1.000 |
Colorectal Cancer Screening |
| CMS130v5 |
2017 |
5.0.000 |
Colorectal Cancer Screening |
Description
Percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer.
Guidance
None
Patient Group Definitions
| Group |
Description |
Instructions Links |
| Initial Population | Patients 50-75 years of age with a visit during the measurement period | Webchart Instructions |
| Denominator | Equals Initial Population | Webchart Instructions |
| Denominator Exclusions | Patients with a diagnosis or past history of total colectomy or colorectal cancer | Webchart Instructions |
| Numerator | Patients with one or more screenings for colorectal cancer. Appropriate screenings are defined by any one of the following criteria:
- Fecal occult blood test (FOBT) during the measurement period
- Flexible sigmoidoscopy during the measurement period or the four years prior to the measurement period
- Colonoscopy during the measurement period or the nine years prior to the measurement period | Webchart Instructions |
| Numerator Exclusions | Not Applicable | Webchart Instructions |
| Denominator Exceptions | None | |
Details
| Full eMeasure Code |
eMeasure Identifier |
Measure Year |
Version |
NQF # |
GUID |
| CMS130v5 |
130 |
2017 |
5.0.000 |
0034 |
aa2a4bbc-864f-45ee-b17a-7ebcc62e6aac |
| Steward |
Developer |
Endorsed By |
| National Committee for Quality Assurance |
National Committee for Quality Assurance |
National Quality Forum |
| Scoring Method |
Measure Type |
Stratification |
Risk Adjustment |
| Proportion |
PROCESS |
None |
None |
Rate Aggregation
None
Improvement Notation
Higher score indicates better quality
Rationale
An estimated 132,700 men and women were diagnosed with colon or rectal cancer in 2015. In the same year, 49,700 were estimated to have died from the disease, making colorectal cancer the third leading cause of cancer death in the United States (National Cancer Institute 2015, American Cancer Society 2015).
Screening for colorectal cancer is extremely important as there are no signs or symptoms of the cancer in the early stages. If the disease is caught in its earliest stages, it has a five-year survival rate of 90%; however, the disease is often not caught this early. While screening is extremely effective in detecting colorectal cancer, it remains underutilized (American Cancer Society 2015).
The U.S. Preventive Services Task Force has identified fecal occult blood tests, colonoscopy, and flexible sigmoidoscopy as effective screening methods (United States Preventive Services Task Force 2008).
Clinical Recommendation Statement
The United States Preventive Services Task Force (2008):
[1] The USPSTF recommends screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing until age 75 years (A recommendation).
[2] The USPSTF concludes that the evidence is insufficient to assess the benefits and harms of computed tomographic (CT) colonography and fecal DNA testing as screening modalities for colorectal cancer (I statement).
Definition
None
Transmission Format
TBD
Applicable Value Sets
| Category |
Value Set |
OID |
| Diagnosis |
Malignant Neoplasm of Colon |
2.16.840.1.113883.3.464.1003.108.12.1001 |
| Encounter, Performed |
Annual Wellness Visit |
2.16.840.1.113883.3.526.3.1240 |
| Encounter, Performed |
Face-to-Face Interaction |
2.16.840.1.113883.3.464.1003.101.12.1048 |
| Encounter, Performed |
Home Healthcare Services |
2.16.840.1.113883.3.464.1003.101.12.1016 |
| Encounter, Performed |
Office Visit |
2.16.840.1.113883.3.464.1003.101.12.1001 |
| Encounter, Performed |
Preventive Care Services - Established Office Visit, 18 and Up |
2.16.840.1.113883.3.464.1003.101.12.1025 |
| Encounter, Performed |
Preventive Care Services-Initial Office Visit, 18 and Up |
2.16.840.1.113883.3.464.1003.101.12.1023 |
| Laboratory Test, Performed |
Fecal Occult Blood Test (FOBT) |
2.16.840.1.113883.3.464.1003.198.12.1011 |
| Patient Characteristic Ethnicity |
Ethnicity |
2.16.840.1.114222.4.11.837 |
| Patient Characteristic Payer |
Payer |
2.16.840.1.114222.4.11.3591 |
| Patient Characteristic Race |
Race |
2.16.840.1.114222.4.11.836 |
| Patient Characteristic Sex |
ONC Administrative Sex |
2.16.840.1.113762.1.4.1 |
| Procedure, Performed |
Colonoscopy |
2.16.840.1.113883.3.464.1003.108.12.1020 |
| Procedure, Performed |
Flexible Sigmoidoscopy |
2.16.840.1.113883.3.464.1003.198.12.1010 |
| Procedure, Performed |
Total Colectomy |
2.16.840.1.113883.3.464.1003.198.12.1019 |
References
American Cancer Society. 2015. "Cancer Prevention & Early Detection Facts & Figures 2015-2016." Atlanta: American Cancer Society.
National Cancer Institute. 2015. "SEER Stat Fact Sheets: Colon and Rectum Cancer." Bethesda, MD, http://seer.cancer.gov/statfacts/html/colorect.html
U.S. Preventive Services Task Force (USPSTF). 2008. "Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement." Ann Intern Med 149(9):627-37.
Disclaimer
These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.
THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.
Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].
Copyright
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
The Measures are copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices). Commercial use is defined as the sale, licensing, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial use of the Measures requires a license agreement between the user and NCQA. NCQA is not responsible for any use of the Measures.
(C) 2008-2016 National Committee for Quality Assurance. All Rights Reserved.
Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications.
CPT(R) contained in the Measure specifications is copyright 2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2015 International Health Terminology Standards Development Organisation. ICD-10 copyright 2015 World Health Organization. All Rights Reserved.
Source:
https://ecqi.healthit.gov/ecqm/measures/cms130v5